Summary
Elite Pharmaceuticals Inc (Elite) is a specialty pharmaceutical company focuses on the development of oral sustained and controlled release products. The company’s product portfolio includes phentermine tablets, Lodrane D, methadone tablets and hydromorphone hydrochloride tablets and dantrolene sodium, among others, which are commercialized products either owned, licensed or contract manufactured. It develops its products in the areas of pain management, bariatric, cardiovascular, infection and allergy. Elite also has pipeline of abuse-deterrent opioids for the treatment of chronic pain. The company uses its proprietary abuse-deterrent technology, ART, for the development and manufacturing of oral, controlled-release products. Elite is headquartered in Northvale, New Jersey, the US.
Elite Pharmaceuticals Inc (ELTP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Elite Pharma Acquires Trimipramine ANDA from Mikah Pharma 11
Partnerships 11
Elite Pharma Enters into Co-Development and Licensing Agreement with SunGen Pharma 11
Elite Pharma Enters into Co-Development and Licensing Agreement with SunGen Pharma 12
Elite Pharma Enters Into Co-Development Agreement With Hong Kong-Based Company 13
Elite Pharma Enters Into Co-Development Agreement With Hi-Tech Pharmacal 13
Licensing Agreements 14
Elite Pharma Enters into Licensing Agreement with Epic Pharma for Abuse-Deterrent ELI-200 14
Elite Pharma Enters Into Licensing Agreement With Epic Pharma For Twelve Generic Products 15
Equity Offering 16
Elite Pharma to Raise Funds through Private Placement of Shares 16
Elite Pharma Announces Private Placement of Shares for USD40 Million 17
Elite Pharma Announces Private Placement Of Common Stock For US$10 Million 18
Elite Pharma Announces Private Placement Of Preferred Stock For US$5 Million 18
Elite Pharmaceuticals Inc - Key Competitors 20
Key Employees 21
Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Jun 14, 2017: Elite Pharmaceuticals, Reports Financial Results for the Fiscal Year Ended March 31, 2017 and Provides Conference Call Information 23
Feb 09, 2017: Elite Pharmaceuticals Reports Results For Third Quarter Of Fiscal Year 2017 24
Nov 09, 2016: Elite Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2017 25
Aug 09, 2016: Elite Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2017 26
Corporate Communications 27
May 04, 2016: Elite Pharmaceuticals Appoints Davis S. Caskey to Its Board of Directors 27
Apr 12, 2016: Elite Pharmaceuticals Announces Changes to their Board of Directors 28
Jan 13, 2016: Nasrat Hakim Named Chairman Of Board Of Directors For Elite Pharmaceuticals 29
Product News 30
Jun 15, 2016: Elite Pharmaceuticals Reports Financial Results for the Fiscal Year Ended March 31, 2016 and Provides Conference Call Information 30
May 09, 2016: Elite Pharmaceuticals to Present SequestOx Data at the American Pain Society 35th Annual Scientific Meeting 31
Feb 09, 2016: Elite Pharmaceuticals Reports Strong Growth For Third Quarter Of Fiscal Year 2016 32
Product Approvals 33
Jul 17, 2016: FDA Issues Complete Response Letter for SequestOx New Drug Application 33
Mar 17, 2016: Elite Announces U.S. FDA Priority Review Designation for SequestOx NDA 34
Jan 13, 2016: FDA Approves Waiver Of NDA Filing Fee For Elite Pharmaceuticals 35
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36
List of Tables
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 1
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Elite Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Elite Pharma Acquires Trimipramine ANDA from Mikah Pharma 11
Elite Pharma Enters into Co-Development and Licensing Agreement with SunGen Pharma 11
Elite Pharma Enters into Co-Development and Licensing Agreement with SunGen Pharma 12
Elite Pharma Enters Into Co-Development Agreement With Hong Kong-Based Company 13
Elite Pharma Enters Into Co-Development Agreement With Hi-Tech Pharmacal 13
Elite Pharma Enters into Licensing Agreement with Epic Pharma for Abuse-Deterrent ELI-200 14
Elite Pharma Enters Into Licensing Agreement With Epic Pharma For Twelve Generic Products 15
Elite Pharma to Raise Funds through Private Placement of Shares 16
Elite Pharma Announces Private Placement of Shares for USD40 Million 17
Elite Pharma Announces Private Placement Of Common Stock For US$10 Million 18
Elite Pharma Announces Private Placement Of Preferred Stock For US$5 Million 18
Elite Pharmaceuticals Inc, Key Competitors 20
Elite Pharmaceuticals Inc, Key Employees 21
Elite Pharmaceuticals Inc, Subsidiaries 22List of Figures
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
